EUVIMEDEUVIMED entdecken
Fallbericht

Daratumumab in the Management of Red Cell Aplasia Following Allogeneic Hematopoietic Stem Cell Transplantation

Nihar Desai iD, Auro Viswabandya iD, Dennis Dong Hwan Kim iD, Jeffrey H Lipton iD, Jonas Mattsson iD, Arjun Datt Law iD

European Journal of Haematology · 2025

DOI: 10.1111/ejh.14341 ↗

Kurz gefasst

Fallbericht in der Zeitschrift European Journal of Haematology, 2025. Verfasst von Nihar Desai und 5 weiteren Autor:innen. Beteiligte Einrichtung: Hans Messner Allogeneic Blood and Marrow Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Canada. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Red-Cell Aplasia, Pure, Antibodies, Monoclonal, Transplantation, Homologous. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 13 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pure red cell aplasia (PRCA) is a rare but significant complication following major ABO‐incompatible allogeneic hematopoietic stem cell transplantation (HSCT). The persistence of recipient B lymphocytes producing anti‐donor isohemagglutinins leads to reticulocytopenia and anemia, often resulting in transfusion dependence. Current treatment options for post‐HSCT PRCA are limited and frequently yield suboptimal responses, complicating patient management. Herein, we report three cases of post‐HSCT PRCA successfully managed with daratumumab, a monoclonal antibody targeting CD38‐expressing plasma cells. All patients demonstrated rapid reticulocyte recovery and transfusion independence after daratumumab treatment, despite prior treatment failures. These findings suggest that daratumumab may provide a more effective therapeutic approach, with a favorable safety profile compared to traditional therapies. Given its demonstrated efficacy and safety, daratumumab warrants consideration as a first‐line treatment for post‐HSCT PRCA, potentially improving patient quality of life and reducing transfusion‐related complications. Further studies should explore optimal dosing and long‐term outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationRed-Cell Aplasia, PureAntibodies, MonoclonalTransplantation, HomologousHumansMaleMiddle AgedFemaleTreatment OutcomeAdultDisease Management

Stichwörter der Autor:innen

Red cell aplasiaimmunotherapytransplantation

Substanzen

daratumumabAntibodies, Monoclonal

Autor:innen und Institutionen

  • Hans Messner Allogeneic Blood and Marrow Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Canada.
  • Temerty faculty of Medicine, University of Toronto, Toronto, Canada.

ORCID-Profile: Nihar Desai, Auro Viswabandya, Dennis Dong Hwan Kim, Jeffrey H Lipton, Jonas Mattsson, Arjun Datt Law

Zitieren

APA

Desai, N., Viswabandya, A., Kim, D. D. H., Lipton, J. H., Mattsson, J., & Law, A. D. (2025). Daratumumab in the Management of Red Cell Aplasia Following Allogeneic Hematopoietic Stem Cell Transplantation. European Journal of Haematology. https://doi.org/10.1111/ejh.14341

Vancouver

Desai N, Viswabandya A, Kim DDH, Lipton JH, Mattsson J, Law AD. Daratumumab in the Management of Red Cell Aplasia Following Allogeneic Hematopoietic Stem Cell Transplantation. European Journal of Haematology. 2025. doi:10.1111/ejh.14341

BibTeX
@article{Desai2025,
  author = {Desai, Nihar and Viswabandya, Auro and Kim, Dennis Dong Hwan and Lipton, Jeffrey H and Mattsson, Jonas and Law, Arjun Datt},
  title = {Daratumumab in the Management of Red Cell Aplasia Following Allogeneic Hematopoietic Stem Cell Transplantation},
  journal = {European Journal of Haematology},
  year = {2025},
  doi = {10.1111/ejh.14341}
}
Kostenlos starten →